Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

Udgivet den 17-05-2016  |  kl. 22:54  |  

Valby, Denmark, 2016-05-17 22:54 CEST (GLOBE NEWSWIRE) -- Valby, Denmark, 17 May 2016 - H. Lundbeck A/S (Lundbeck) hereby reports transactions made by executives and persons and legal entities closely associated to them with shares and linked securities in Lundbeck, cf. Section 28a of the Danish Securities Trading Act.

Name:                                                                                    Anders Gersel Pedersen

Job position:                                                                         Executive Vice President, member of the Executive

                                                                                            Management

ID code (ISIN code):                                                            DK 0010287234

Name of the issuer of the securities:                                   H. Lundbeck A/S

Description of the security:                                                Shares

Nature of the transaction:                                                  Sale of shares

Date of trading:                                                                  12 May 2016

Market on which the trading was affected:                        Nasdaq OMX Copenhagen

Number of traded securities:                                            33,000 shares

Total market price of securities traded:                             DKK 7,956,000

  

As part of Lundbeck's incentive programme for 2012, the below mentioned executive has exercised warrants.

Name:                                                                                    Anders Gersel Pedersen

Job position:                                                                         Executive Vice President, member of the Executive

                                                                                             Management

ID code (ISIN code):                                                            DK 0010287234

Name of the issuer of the securities:                                   H. Lundbeck A/S

Description of the security:                                                  Warrants

Nature of the transaction:                                                    Exercise of warrants

Date of trading:                                                                    17 May 2016

Market on which the trading was affected:                        Nasdaq OMX Copenhagen

Number of traded securities:                                             20,000

Total market price of securities traded:                             DKK 4,752,000

 

Persons under obligation to report such transactions are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities could include but is not limited to:

•               spouse or cohabitant

•               children below the age of 18, provided that the executive is the custody holder

•               legal entities in which the executive has a controlling influence

 

Lundbeck contacts

Investors: Media:
   
Palle Holm Olesen Mads Kronborg
Vice President,  Investor Relations Senior Director, Corp. Communication
palo@lundbeck.com mavk@lundbeck.com
+45 30 83 24 26 +45 36 43 30 00

 

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders - we call this Progress in Mind.

Our approximately 5,300 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated core revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.

Vedhæftede filer:

Executive_trade_UK 17052016.pdf

Udgivet af: NPinvestordk

Seneste nyheder

10:14 Vestas og fransk NKT-konkurrent sænket til "underperform" af finansgigant efter Trump-sejr
09:53 Torm er presset af lavere olietransport ud af Mellemøsten - topchef tror på genopretning
09:39 DFDS-topchef: Finansiel præstation i Ekol-handel blandt årsagerne til aflyst køb
09:25 Aktier/åbning: Lidt højere marked med flotte plusser til GN, Novonesis og Genmab
09:14 Novonesis overrasker med oppræcisering i stærkt tredje kvartal
09:08 Ambus kursmål skåret til 130 kr. efter regnskab hos Redburn
09:06 Obligationer/åbning: Stort set uændret rente på dag med rentemøder
09:02 DFDS' Torben Carlsen ser først økonomisk afmatning i Europa vende i 2025
08:58 Torm fortsætter vækst og betaler udbytte - men lavere fragtpriser giver nedjustering
08:45 Vestas får sænket anbefaling af Bank of America efter Trump-sejr og regnskab
08:31 GN-topchef: Vi når formentlig ikke vending til positivt marked i Enterprise i år
08:31 Aktier/tendens: Ny stime af regnskaber - opjustering fra Novonesis, Genmab, men GN sænker
08:23 Gubra vender driftsindtjeningen til plus i tredje kvartal drevet af fedme
07:49 DFDS' fragtmængder og passagerantal hjulpet af rutetilgang
07:45 Korr: Obligationer/tendens: Udsigt til uændret åbning på dag med rentemøder
07:37 Genmabs lukning i USA indikerer positiv åbning
07:35 Zealand Pharma OVERBLIK Q3: Opmuntrende pipeline overskygger underskud
07:27 Obligationer/tendens: Udsigt til uændret åbning på dag med rentemøder
07:07 Genmabs kursmål sættes ned af amerikanske TD Cowen efter regnskab
07:05 Ørsteds kursmål sænkes hos HSBC efter regnskab og Trump-sejr